Sanofi’s sunny forecast for Dupixent and its aging diabetes drugs just might be achievable: analyst

13th February 2020 Uncategorised 0

Can Sanofi’s new CEO Paul Hudson really grow sales of its atopic dermatitis drug Dupixent to €10 billion and stabilize the company’s long-suffering diabetes franchise? Don’t count him out, analysts at SVBLeerink figure. And they have math to make their case.

More: Sanofi’s sunny forecast for Dupixent and its aging diabetes drugs just might be achievable: analyst
Source: fierce